Literature DB >> 10069390

Identification of caspases that cleave presenilin-1 and presenilin-2. Five presenilin-1 (PS1) mutations do not alter the sensitivity of PS1 to caspases.

M van de Craen1, C de Jonghe, I van den Brande, W Declercq, G van Gassen, W van Criekinge, I Vanderhoeven, W Fiers, C van Broeckhoven, L Hendriks, P Vandenabeele.   

Abstract

Mutations in the presenilin (PS) genes PSI and PS2 are involved in Alzheimer's disease (AD). Recently, apoptosis-associated cleavage of PS proteins was identified. Here we demonstrate that PS1 as well as PS2 are substrates for different members of the caspase protein family. Remarkably, the caspases acting on PS1 could be subdivided in two groups. One group, containing caspase-8, -6 and -11, cleaved PSI after residues ENDD329 and to a lesser extent after residues AQRD341. A second group consisting of caspase-3, -7 and -1 acted uniquely on AQRD341. Importantly, these two cleavage sites were also recognized by caspases in the C-terminal PS1 fragment produced by constitutive proteolysis. In decreasing order of activity, caspase-8, -3, -1, -6 and -7 proteolysed PS2 at the recognition site D326SYD329. Caspase-8 and -3 exhibited the highest proteolytic activity on both PS1 and PS2. PS1 and PS2 were not hydrolyzed by caspase-2 and PS2 also not by caspase-11. None of five missense mutations affected the sensitivity of PSI to caspase-mediated cleavage. This suggests that AD pathogenesis associated with PS1 missense mutations cannot be explained by a change in caspase-dependent processing.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10069390     DOI: 10.1016/s0014-5793(99)00108-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  19 in total

Review 1.  Presenilins: structural aspects and posttranslational events.

Authors:  F Checler
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

Review 2.  Metabolism of presenilins.

Authors:  G Thinakaran
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

Review 3.  The kinder side of killer proteases: caspase activation contributes to neuroprotection and CNS remodeling.

Authors:  B McLaughlin
Journal:  Apoptosis       Date:  2004-03       Impact factor: 4.677

4.  Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death.

Authors:  C Stadelmann; T L Deckwerth; A Srinivasan; C Bancher; W Brück; K Jellinger; H Lassmann
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

5.  Presenilin 1 forms aggresomal deposits in response to heat shock.

Authors:  Imre Kovacs; Kristen M Lentini; Laura MacKenzie Ingano; Dora M Kovacs
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

Review 6.  Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease.

Authors:  Zhao Zhong Chong; Faqi Li; Kenneth Maiese
Journal:  Brain Res Brain Res Rev       Date:  2005-01-08

Review 7.  The Role of Neuronal NLRP1 Inflammasome in Alzheimer's Disease: Bringing Neurons into the Neuroinflammation Game.

Authors:  Jeremy Kean Yi Yap; Benjamin Simon Pickard; Elaine Wan Ling Chan; Sook Yee Gan
Journal:  Mol Neurobiol       Date:  2019-05-20       Impact factor: 5.590

Review 8.  Employing new cellular therapeutic targets for Alzheimer's disease: a change for the better?

Authors:  Zhao Zhong Chong; Faqi Li; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2005-01       Impact factor: 1.990

9.  Early changes in behavior deficits, amyloid beta-42 deposits and MAPK activation in doubly transgenic mice co-expressing NSE-controlled human mutant PS2 and APPsw.

Authors:  Dae Y Hwang; Jung S Cho; Jae H Oh; Sun B Shim; Seung W Jee; Su H Lee; Su J Seo; Chi W Song; Seok H Lee; Yong K Kim
Journal:  Cell Mol Neurobiol       Date:  2005-08       Impact factor: 5.046

Review 10.  Molecular basis of etiological implications in Alzheimer's disease: focus on neuroinflammation.

Authors:  Rituraj Niranjan
Journal:  Mol Neurobiol       Date:  2013-02-19       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.